iNKT cells as drivers for preterm labour

iNKT 细胞作为早产的驱动因素

基本信息

  • 批准号:
    MR/L002647/1
  • 负责人:
  • 金额:
    $ 16.03万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2013
  • 资助国家:
    英国
  • 起止时间:
    2013 至 无数据
  • 项目状态:
    已结题

项目摘要

The purpose of this work is to develop treatments to prevent preterm birth. Preterm birth is a big health problem. Globally, over 1 million children die each year from the complications of preterm birth. In the UK around 55,000 babies (around 7.8% of all UK births) are born preterm. Despite much effort, these rates are rising. Although survival rates are improving, with 77% of UK babies born at 26 weeks gestation now leaving hospital, survivors are at increased risk of short term morbidity and long term disability. Long term disability includes respiratory problems, motor and sensory impairment, learning difficulties, and social and behavioral difficulties and is driven not only by the consequences of prematurity, but by the intrauterine inflammation which precedes prematurity. Together the complications of preterm birth result in a £2.946 billion estimated annual costs of preterm birth to the public purse in England and Wales (2006 prices). Unfortunately, there are hardly any treatments in development for preterm birth. Even if we use all the treatments we currently have for all women at risk, preterm birth rates will only fall by 0.2% in the UK i.e., from 7.8% to 7.6%. We and others have suggested that this lack of good treatments, and the lack of treatments in development is because we don't properly understand what causes women to go into preterm labour, nor do we understand what triggers labour at term.We and others have shown that "inflammation" is key to the start of labour, both at term and preterm. We have tried several strategies to treat inflammation and hence prevent preterm labour, but none has yet been effective. We think this is because we are trying to stop inflammation well after it has started. We are now going to look at some immune cells which are involved in the start of the inflammatory process and which have been shown to be important in stimulating preterm labour in a mouse model. These cells (invariant [i] NKT cells) are important because they link two halves of the immune system, and because they can respond rapidly to "danger" signals, including those present in pregnant women.In this study we are going to look at these cells in the place that we think that labour starts - the lining of the womb which separates mother from baby. We will see what happens in the lining of the womb in labour, and then look at how the iNKT cells change in the lining of the womb in labour. We will see if we can start labour in a mouse model by stimulating these iNKT cells, and then see if drugs which prevent iNKT activation can prevent inflammation induced preterm labour. Next, we will look to see if these iNKT cells are activated early in the process of labour - we think they will be. Lastly, we will see how progesterone, which is currently used to treat preterm labour in some women, might affect iNKT cells.We believe our work will generate new understanding of how labour starts, and so ultimately develop treatments to prevent preterm labour. Such treatments could make major inroads into preventing the deaths of up to 1 million children per year.
这项工作的目的是开发预防早产的治疗方法。早产是一个严重的健康问题。在全球范围内,每年有100多万儿童死于早产并发症。在英国,约有55,000名婴儿(约占英国出生人口的7.8%)早产。尽管付出了很大努力,这些比率仍在上升。虽然存活率正在提高,77%的英国婴儿在妊娠26周时出生,现在离开医院,幸存者的短期发病率和长期残疾的风险增加。长期残疾包括呼吸问题、运动和感觉障碍、学习困难以及社会和行为困难,不仅是由早产的后果造成的,而且是由早产前的宫内炎症造成的。早产并发症导致英格兰和威尔士公共财政每年估计早产费用为29.46亿英镑(2006年价格)。不幸的是,几乎没有任何治疗早产的方法。即使我们对所有有风险的妇女使用目前所有的治疗方法,英国的早产率也只会下降0.2%,从7.8%下降到7.6%。我们和其他人认为,这种缺乏良好的治疗方法,以及缺乏发育中的治疗方法是因为我们没有正确理解是什么原因导致妇女进入早产,我们也不知道是什么触发了足月分娩。我们和其他人已经表明,“炎症”是分娩开始的关键,无论是在足月还是早产。我们已经尝试了几种策略来治疗炎症,从而预防早产,但没有一种有效。我们认为这是因为我们试图在炎症开始后很好地阻止炎症。我们现在将研究一些免疫细胞,它们参与炎症过程的开始,并且已被证明在小鼠模型中刺激早产方面很重要。这些细胞(不变的NKT细胞)非常重要,因为它们连接着免疫系统的两个部分,并且它们可以对“危险”信号做出快速反应,包括孕妇体内的那些。在这项研究中,我们将在我们认为分娩开始的地方观察这些细胞--将母亲和婴儿分开的子宫内膜。我们将看到在分娩时子宫内膜发生了什么,然后看看iNKT细胞在分娩时子宫内膜的变化。我们将看看我们是否可以通过刺激这些iNKT细胞在小鼠模型中开始分娩,然后看看阻止iNKT激活的药物是否可以预防炎症诱导的早产。接下来,我们将观察这些iNKT细胞是否在分娩过程的早期被激活-我们认为它们会被激活。最后,我们将看到孕酮,这是目前用于治疗早产的一些妇女,可能会影响iNKT细胞。我们相信我们的工作将产生新的理解如何劳动开始,从而最终开发治疗,以防止早产。这种治疗方法可以在防止每年多达100万儿童死亡方面取得重大进展。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
15-epi-lipoxin A4 reduces the mortality of prematurely born pups in a mouse model of infection-induced preterm birth.
  • DOI:
    10.1093/molehr/gau117
  • 发表时间:
    2015-04
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Rinaldi SF;Catalano RD;Wade J;Rossi AG;Norman JE
  • 通讯作者:
    Norman JE
Crosstalk between monocytes and myometrial smooth muscle in culture generates synergistic pro-inflammatory cytokine production and enhances myocyte contraction, with effects opposed by progesterone.
  • DOI:
    10.1093/molehr/gav027
  • 发表时间:
    2015-08
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Rajagopal SP;Hutchinson JL;Dorward DA;Rossi AG;Norman JE
  • 通讯作者:
    Norman JE
Decidual neutrophil infiltration is not required for preterm birth in a mouse model of infection-induced preterm labor.
Immune cell and transcriptomic analysis of the human decidua in term and preterm parturition.
  • DOI:
    10.1093/molehr/gax038
  • 发表时间:
    2017-10-01
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Rinaldi SF;Makieva S;Saunders PT;Rossi AG;Norman JE
  • 通讯作者:
    Norman JE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jane Norman其他文献

Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT
  • DOI:
    10.1016/j.ijgo.2015.02.008
  • 发表时间:
    2015-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Peter von Dadelszen;Laura A. Magee;Beth A. Payne;Dustin T. Dunsmuir;Sharla Drebit;Guy A. Dumont;Suellen Miller;Jane Norman;Lee Pyne-Mercier;Andrew H. Shennan;France Donnay;Zulfiqar A. Bhutta;J. Mark Ansermino
  • 通讯作者:
    J. Mark Ansermino
Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?
  • DOI:
    10.1182/blood-2022-159217
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Stephen Boyle;Robin Sanderson;Maeve A. O'Reilly;Tobias F. Menne;Jane Norman;Adrian Bloor;Sanne Lugthart;Sridhar Chaganti;Carlos Gonzalez-Arias;Ceri Jones;Anne-Louise Latif;Reuben Benjamin;Piers Patten;Deborah Yallop;Victoria Potter;Claire Roddie;Andrea Kuhnl
  • 通讯作者:
    Andrea Kuhnl
A systematic review of risk assessment strategies for populations at high risk of engaging in violent
对参与暴力高风险人群的风险评估策略进行系统审查
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    R. Whittington;Jc Hockenhull;J. Mcguire;M. Leitner;W. Barr;M. Cherry;R. Flentje;B. Quinn;Y. Dundar;R. Dickson;Whittington R;Hockenhull Jc;Barr W Cherry;Ken Stein;Martin Ashton;Matthias Beck;Aileen Clarke;Peter Davidson;Elaine Mccoll Director;William Mcguire;Geoffrey Meads;Jane Norman;John Powell;James Raftery;Helen Roberts;Helen Snooks
  • 通讯作者:
    Helen Snooks
Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
  • DOI:
    10.1182/blood-2024-200738
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Andrea Kuhnl;Amy A Kirkwood;Claire Roddie;Caroline Besley;Jane Norman;Ben Uttenthal;Frances Seymour;Andrew J. Davies;Wendy Osborne;William Townsend;Emil Arjun Kumar;Amrith Mathew;Carlos Gonzalez Arias;Ceri Jones;Aikaterini Panopoulou;Ahmed Abdulgawad;Edward Bataillard;Pierre McCarthy;Nicolas Martinez-Calle;Vaishali Dulobdas
  • 通讯作者:
    Vaishali Dulobdas
<strong>ABO blood group antigens and preterm birth risk</strong>
  • DOI:
    10.1016/j.jri.2023.104083
  • 发表时间:
    2023-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Katherine Mountain;David MacIntyre;Denise Chan;Alice Hyde;James Pasint-Magyar;Yun Lee;Richard Brown;Anna David;Anne Dell;Ten Feizi;Stuart Haslam;Yan Liu;Holly Lewis;Jane Norman;Sarah Stock;Tiong Teoh;Vasso Terzidou;Samit Kundu;Phillip Bennett;Lynne Sykes
  • 通讯作者:
    Lynne Sykes

Jane Norman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jane Norman', 18)}}的其他基金

MICA: A pragmatic approach to the prevention of gestational diabetes and pre-eclampsia in obese pregnant women in resource poor settings
MICA:资源匮乏地区肥胖孕妇预防妊娠期糖尿病和先兆子痫的实用方法
  • 批准号:
    MR/R019142/1
  • 财政年份:
    2018
  • 资助金额:
    $ 16.03万
  • 项目类别:
    Research Grant
Does metformin reduce excess birthweight in offspring of obese pregnant women?
二甲双胍是否可以减少肥胖孕妇的后代的超重出生体重?
  • 批准号:
    MC_G1002463
  • 财政年份:
    2010
  • 资助金额:
    $ 16.03万
  • 项目类别:
    Intramural
Does progesterone prophylaxis to prevent preterm labour improve outcome? (OPPTIMUM)
使用黄体酮预防早产是否可以改善结局?
  • 批准号:
    G0700452/1
  • 财政年份:
    2008
  • 资助金额:
    $ 16.03万
  • 项目类别:
    Research Grant

相似国自然基金

分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
  • 批准号:
    82371801
  • 批准年份:
    2023
  • 资助金额:
    47.00 万元
  • 项目类别:
    面上项目
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
  • 批准号:
    82371631
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
亚低温调控颅脑创伤急性期神经干细胞Mpc2/Lactate/H3K9lac通路促进神经修复的研究
  • 批准号:
    82371379
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
缺氧诱导因子(HIF)-2α转录抑制树突状细胞CD36表达减轻肾脏缺血再灌注损伤的机制
  • 批准号:
    82370751
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
视网膜色素上皮细胞中YAP/mtDNA/cGAS-炎症小体轴在干性年龄相关性黄斑变性中的作用
  • 批准号:
    82371073
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
TRIM25-PHGDH信号轴调控脓毒症肺上皮细胞铁死亡的机制研究
  • 批准号:
    82372151
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
CD8+T细胞亚群在抗MDA5抗体阳性皮肌炎中的致病机制研究
  • 批准号:
    82371805
  • 批准年份:
    2023
  • 资助金额:
    45.00 万元
  • 项目类别:
    面上项目
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
  • 批准号:
    82370981
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目

相似海外基金

Integrated Molecular and Cellular Drivers of Alveologenesis
肺泡发生的综合分子和细胞驱动因素
  • 批准号:
    10637764
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
选择性剪接的细胞表面蛋白作为白血病发生的驱动因素和免疫治疗的靶点
  • 批准号:
    10648346
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition
绘制头颈部癌前侵袭性疾病转变的免疫基因组驱动因素
  • 批准号:
    10770868
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture
非西班牙裔黑人 HCC 的基因组和环境驱动因素:先天和后天
  • 批准号:
    10856546
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Extracellular drivers of myocyte stiffening in diastolic heart disease
舒张性心脏病心肌细胞僵硬的细胞外驱动因素
  • 批准号:
    10936206
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis
横纹肌肉瘤细胞状态、癌症干细胞和转移的致癌驱动因素
  • 批准号:
    10658091
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
The Cholangiocarcinoma Conference: Molecular Drivers, Microenvironment, and Precision Medicine
胆管癌会议:分子驱动因素、微环境和精准医学
  • 批准号:
    10747566
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Systematic Characterization and Targeting of Neomorphic Drivers in Cancer
癌症新形态驱动因素的系统表征和靶向
  • 批准号:
    10717973
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Autoimmune Drivers and Protectors Team Science (ADAPTS)
自身免疫驱动器和保护器团队科学 (ADAPTS)
  • 批准号:
    10657232
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
Epigenomic Drivers of EBV Epithelial Cancers
EB 病毒上皮癌的表观基因组驱动因素
  • 批准号:
    10627690
  • 财政年份:
    2023
  • 资助金额:
    $ 16.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了